SAN DIEGO, Nov. 18, 2015 /PRNewswire/ -- Kerastem, a worldwide leader in cell-based approaches to hair regeneration, announced today that STYLE, the company's phase II clinical study investigating early stage female and male pattern baldness is now recruiting patients in Los Angeles and Miami.
Dr. Joel Aronowitz, a participating investigator and Director, University Stem Cell Center (located at Cedars-Sinai in Los Angeles), is now actively screening and recruiting potential subjects for STYLE. According to Dr. Aronowitz, a respected expert in the field of regenerative medicine, "We are pleased to participate in STYLE and be able to offer both women and men the opportunity to enroll in this innovative study." Added Dr. Aronowitz, "Effective immediately, we are available to screen potential subjects to determine their candidacy for participation in STYLE."
In Miami, Dr. Jeffrey Epstein, participating investigator and Medical Director of The Foundation for Hair Restoration, has also received approval to begin recruiting patients for STYLE. For Dr. Epstein, a recognized leader in the field of hair restoration for over 20 years, "STYLE represents a new potential approach in the treatment of male and female pattern hair loss—the most common form of alopecia." Added Dr. Epstein, "We are delighted to begin screening subjects and look forward to seeing the clinical outcomes of STYLE."
STYLE is Kerastem's phase II, randomized, blinded, and controlled investigation of Kerastem Therapy in early stage female and male pattern baldness. STYLE is approved to enroll up to 70 patients at up to eight (8) centers within the United States.
Outside of the United States, the company is actively involved in market development, with Kerastem Therapy currently offered at a number of clinics in Europe & Japan. To learn more about Kerastem or the STYLE Clinical Trial, please visit www.kerastem.com.
Kerastem is a leader in the development and commercialization of cell-based approaches to hair loss. The private company is a wholly owned subsidiary of Bimini Technologies. The Bimini portfolio also includes Puregraft, the world's leading fat transfer solution.
SOURCE Kerastem Technologies